39th Annual J.P. Morgan Healthcare Conference
Receive updates straight into your inbox
Sutro Biopharma, located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company creating a broad variety of next-generation protein therapeutics for oncology based on its proprietary, cell-free protein synthesis platform, XpressCF.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
Sutro designs cytokine-based immuno-oncology therapies, antibody-drug conjugates, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and development of first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.
Sutro Biopharma, Inc.
310 Utah Avenue
Suite 150
South San Francisco, CA 94080
Sutro Biopharma
Annie J. Chang
Head of Investor Relations
T: 650-801-5728
ajchang@sutrobio.com
Russo Partners
David Schull
T: (212) 845-4271
david.schull@russopartnersllc.com
Russo Partners
Maggie Beller
T: (646) 942-5631
maggie.beller@russopartnersllc.com